quadrivalent recombinant hemagglutinin influenza vaccine (VAX2012Q) / VaxInnate - LARVOL DELTA

Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in Western Australia. (PubMed) - "No serious vaccine-associated adverse events were detected during follow-up of either vaccine. Acknowledging the study limitations, the results of this post-marketing surveillance support the safety of QIV, suggesting there is little difference in the reactogenicity of QIV as compared to TIV."

Journal • Biosimilar • Pain

Vaccine recommendations for children and youth for the 2015/2016 influenza season. (PubMed) - Paediatr Child Health - "The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization for the 2015/2016 influenza season include some important changes: Children and adolescents with neurological or neurodevelopmental disorders were added to the list of individuals considered to be at high risk for severe influenza.Quadrivalent influenza vaccines are recommended preferentially over trivalent vaccines for use in children and youth.An adjuvanted trivalent inactivated influenza vaccine is now available for use in children six to 23 months of age."

Journal • Biosimilar • Leukemia

Cost-Effectiveness Analysis Of Quadrivalent Influenza Vaccine In Spain. (PubMed) - Hum Vaccin Immunother - "Probabilistic sensitivity analysis show ICER below 30,000€/QALY in 96% of simulations. Replacing TIVs with QIV in Spain could improve influenza prevention by avoiding B virus mismatch and provide a cost-effective healthcare intervention."

Journal • Biosimilar

Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. (PubMed) - "In adults, inactivated QIV was as immunogenic as seasonal TIV, with equivalent efficacy against the shared three strains included in TIV, and a superior immunogenicity against the non-TIV B lineage."

Journal • Review • Biosimilar • CNS Disorders • Pain

Circulation of influenza B lineages in northern Viet Nam, 2007-2014. (PubMed) - Western Pac Surveill Response J - "The seasonality of influenza B activity is more variable in tropical and subtropical regions than in temperate zones. Our data showed a common co-circulation of both influenza B lineages in northern Viet Nam, and it was difficult to predict which one was the predominant lineage. Quadrivalent influenza vaccines containing both lineages may improve the effectiveness of influenza vaccine programmes in the future."

Journal • Biosimilar • Complement-mediated Rare Disorders

Potential impact of B lineage mismatch on trivalent influenza vaccine effectiveness during the 2015-2016 influenza season among nursery school children in Suzhou, China. (PubMed, Hum Vaccin Immunother) - "The VE for A(H1N1)pdm09 was moderate but not significant. Mismatching of B lineage may have compromised trivalent influenza vaccine effectiveness during the 2015-2016 influenza season among nursery school children in Suzhou, China. Additional larger studies are warranted to inform policy related to quadrivalent influenza vaccine licensure in China in the future."

Journal • Biosimilar

Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: a Phase III, double-blind, multicenter, randomized, non-inferiority study. (PubMed) - Hum Vaccin Immunother - "The results indicate that QIVc is immunogenic and well tolerated in both younger and older adults. The immunogenicity and safety profiles of QIVc and TIVc were comparable at all ages evaluated."

Journal • Biosimilar • Pain

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17. (clinicaltrials.gov) - P3; N=1556; Completed; Sponsor: Laboratorios Liomont; Active, not recruiting ➔ Completed

Clinical • Trial completion

Evaluation of a Recombinant Quadrivalent Influenza Vaccine Versus a Marketed Quadrivalent Inactivated Influenza Vaccine in Children 3 to 17. (clinicaltrials.gov) - P3; N=1556; Active, not recruiting; Sponsor: Laboratorios Liomont; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed